線維筋痛症治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 17
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 23
3.2 Classification 27
3.3 Symptoms 28
3.4 Quality of Life 28
4 Epidemiology 29
4.1 Disease Background 29
4.2 Risk Factors and Comorbidities 29
4.3 Global Trends 31
4.3.1 US 33
4.3.2 5EU 33
4.3.3 Japan 33
4.4 Forecast Methodology 34
4.4.1 Sources Used 34
4.4.2 Sources Not Used 38
4.4.3 Forecast Assumptions and Methods – Total Prevalent Cases of Fibromyalgia 39
4.4.4 Forecast Assumptions and Methods – Fibromyalgia Pain Severity 41
4.5 Epidemiological Forecast for Fibromyalgia (2013-2023) 42
4.5.1 Total Prevalent Cases of Fibromyalgia 42
4.5.2 Age-Specific Total Prevalent Cases of Fibromyalgia 44
4.5.3 Sex-Specific Total Prevalent Cases of Fibromyalgia 46
4.5.4 Age-Standardized Total Prevalence of Fibromyalgia 48
4.5.5 Total Prevalent Cases of Fibromyalgia by Pain Severity 50
4.6 Discussion 51
4.6.1 Epidemiological Forecast Insight 51
4.6.2 Limitations of the Analysis 53
4.6.3 Strengths of the Analysis 53
5 Disease Management 55
5.1 Diagnosis and Treatment Overview 55
5.1.1 Diagnosis 55
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 57
5.1.3 Clinical Practice 59
5.2 US 61
5.3 France 63
5.4 Germany 65
5.5 Italy 67
5.6 Spain 69
5.7 UK 71
5.8 Japan 73
6 Competitive Assessment 75
6.1 Overview 75
6.2 Product Profiles 76
6.2.1 Cymbalta (duloxetine) 76
6.2.2 Savella (milnacipran) 80
6.2.3 Lyrica (pregabalin) 85
6.2.4 Neurontin (gabapentin) 90
6.2.5 Other Antidepressants 94
6.2.6 Opioids 101
6.2.7 Cyclobenzaprine 106
7 Unmet Need and Opportunity 110
7.1 Overview 110
7.2 More Effective and Well-Tolerated Therapies 111
7.2.1 Unmet Need 111
7.2.2 Gap Analysis 113
7.2.3 Opportunity 113
7.3 Increased Drug Approvals 113
7.3.1 Unmet Need 113
7.3.2 Gap Analysis 114
7.3.3 Opportunity 115
7.4 Increased Physician/Patient Awareness and Earlier Diagnosis 115
7.4.1 Unmet Need 115
7.4.2 Gap Analysis 116
7.4.3 Opportunity 116
7.5 Diagnostic Tools 117
7.5.1 Unmet Need 117
7.5.2 Gap Analysis 118
7.5.3 Opportunity 118
8 Pipeline Assessment 119
8.1 Overview 119
8.2 Clinical Trial Mapping 119
8.2.1 Clinical Trials by Class of Therapy 119
8.3 Promising Drugs in Clinical Development 120
8.3.1 Lyrica CR (pregabalin) 123
8.3.2 DS-5565 (mirogabalin) 129
8.3.3 TNX-102 SL (cyclobenzaprine) 135
8.3.4 TD-9855 143
8.4 Other Drugs in Development 148
9 Current and Future Players 149
9.1 Overview 149
9.2 Trends in Corporate Strategy 152
9.3 Company Profiles 153
9.3.1 Pfizer 153
9.3.2 Eli Lilly 156
9.3.3 Forest Laboratories (Actavis) 160
9.3.4 Daiichi Sankyo 163
9.3.5 Tonix Pharmaceuticals 166
9.3.6 Theravance Biopharma 169
10 Market Outlook 172
10.1 Global Markets 172
10.1.1 Forecast 172
10.1.2 Drivers and Barriers – Global Issues 176
10.2 United States 177
10.2.1 Forecast 177
10.2.2 Key Events 181
10.2.3 Drivers and Barriers 181
10.3 5EU 182
10.3.1 Forecast 182
10.3.2 Key Events 187
10.3.3 Drivers and Barriers 187
10.4 Japan 189
10.4.1 Forecast 189
10.4.2 Key Events 192
10.4.3 Drivers and Barriers 192
11 Appendix 194
11.1 Bibliography 194
11.2 Abbreviations 203
11.3 Methodology 208
11.4 Forecasting Methodology 208
11.4.1 Diagnosed Fibromyalgia Patients 209
11.4.2 Percentage of Drug-Treated Patients 209
11.4.3 Drugs Included in Each Therapeutic Class 209
11.4.4 Launch and Patent Expiry Dates 209
11.4.5 General Pricing Assumptions 210
11.4.6 Individual Drug Assumptions 211
11.4.7 Generic Erosion 214
11.4.8 Pricing of Pipeline Agents 214
11.5 Primary Research – KOLs Interviewed for This Report 215
11.6 Primary Research – Prescriber Survey 216
11.7 About the Authors 217
11.7.1 Analyst 217
11.7.2 Therapy Area Director 217
11.7.3 Epidemiologist 218
11.7.4 Global Head of Healthcare 218
11.8 About GlobalData 219
11.9 Disclaimer 219